Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
News and Events
Panel: Drug Pricing and Value Based Reimbursement
Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors -- about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.
October 13, 2019
October 15, 2019
Laguna Beach, CA
Real-World Noise, Trends, Realities, and Implications on the Road to Value-Based Contracting in Cancer Care
Speaker: Jeff Berkowitz
Value-based pharma contracts have been rare in oncology relative to other therapeutic categories — and for a variety of good and bad reasons. But in the hyper-competitive future, risk-sharing will become a necessary component in every oncology company’s strategic toolkit. In five separate sessions at the value-based cancer summit in NY Oct 16-18, Real Endpoints CEO Jeff Berkowitz and Chairman Roger Longman will help lay out the challenges and the unexploited opportunities in oncology VBAs
October 16, 2019
October 18, 2019
New York, NYevent >
by University of Colorado
Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), to women under the age of 35. It represents a first-of-its-kind published analysis of results from a risk-sharing agreement between biotechnology company Illumina, Inc. and insurer Harvard Pilgrim Health Care, conducting the research in partnership with advisory firm Real Endpoints to evaluate the impacts of the agreement.
October 8, 2019
EurekAlertread full press release >
Recent Insightsview archive >
June 11, 2019
Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. Payers are open to innovative financing models that improve financial predictability and reward clinical performance.read full insight article >
February 13, 2019
How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."read full insight article >
National Business Director
Top 5 Pharma
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
President , GlaxoSmithKline U.S.